Form 4: Vir Biotechnology Director Boosts Stake with Significant Equity and Option Grants

Vir Biotechnology, Inc. Director Charles Elliott Sigal has acquired 8,000 restricted stock units and 16,000 stock options, increasing his direct beneficial ownership in the company.

Summary

• Charles Elliott Sigal, a Director of Vir Biotechnology, Inc. (VIR), acquired 8,000 shares of common stock in the form of Restricted Stock Units (RSUs) on May 30, 2025, at a price of $0.
• These RSUs were granted pursuant to the Issuer's Equity Incentive Plan and are scheduled to vest in full on May 30, 2026.
• Additionally, Mr. Sigal acquired 16,000 stock options with an exercise price of $4.94 per share on May 30, 2025.
• These stock options will vest and become exercisable in full on May 30, 2026, and have an expiration date of May 29, 2035.
• Following these transactions, Mr. Sigal directly beneficially owns 31,806 shares of common stock and 16,000 derivative securities (stock options).
• He also indirectly beneficially owns 10,000 shares of common stock through Sigal Family Investments, LLC, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The acquisition of additional equity by a director, especially through incentive plans, is a strong positive signal of confidence in the company's future and aligns insider interests with shareholders. There are no negative aspects reported in this filing.

Positives

• Director Charles Elliott Sigal acquired 8,000 Restricted Stock Units (RSUs) and 16,000 stock options, significantly increasing his direct beneficial ownership in the company.
• The acquisition of additional equity by a director aligns their interests with those of shareholders, often signaling confidence in the company's future performance and strategic direction.
• The RSUs were acquired at a price of $0, indicating they are part of an incentive plan, which is a common and effective compensation method for directors to encourage long-term commitment and performance.
• The stock options, with an exercise price of $4.94, provide a potential upside for the director if the company's stock price appreciates above this level, further incentivizing performance.

Future Outlook

The acquired Restricted Stock Units and stock options are scheduled to vest in full on May 30, 2026, indicating a future milestone for the director's equity compensation and continued alignment with the company's long-term performance.

Industry Context

This Form 4 filing represents a routine insider transaction for a director at a biotechnology company. Equity grants and acquisitions are standard practices in the biotech industry, serving as a key component of executive and director compensation to align their financial interests with the company's long-term success and shareholder value creation.

Related Party Transactions

• Indirect beneficial ownership of 10,000 shares of common stock through Sigal Family Investments, LLC, with the reporting person disclaiming beneficial ownership except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership, potentially signaling confidence in future stock performance and long-term value creation.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on May 30, 2026.
• The stock options will remain exercisable until their expiration date of May 29, 2035.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, RSUs, Stock Options, Director Ownership, Equity Incentive Plan, Biotechnology